FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Clinical trials for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) explained in plain language.
Never miss a new study
Get alerted when new FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) trials appear
Sign up with your email to follow new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First-of-its-Kind cancer vaccine trial targets rare liver tumor
Disease control Recruiting nowThis early-stage study is testing a new personalized vaccine designed to teach the immune system to attack fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer. The vaccine is given alongside two immunotherapy drugs (nivolumab and ipilimumab) to boost the body's canc…
Matched conditions: FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
First-of-its-Kind vaccine aims to stop rare liver cancer from coming back
Disease control Recruiting nowThis early-stage trial is testing a new personalized vaccine for patients with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC). The vaccine is designed to teach the patient's own immune system to recognize and attack any remaining cancer cells after initia…
Matched conditions: FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Phase: PHASE1 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC